BILHI
LIVE

Serial Number

79244386

Owner

GENEPRED BIOTECHNOLOGIES

Attorney

Lawrence H. Binderow

Filing Date

Jul 23, 2018

Add to watchlist:

No watchlists yet
View on USPTO

BILHI Trademark

Serial Number: 79244386 • Registration: 5809424

BILHI is a trademark filed by GENEPRED BIOTECHNOLOGIES on July 23, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

GENEPRED BIOTECHNOLOGIES

19 rue Roux de Brignolles

Entity Type: 34

Trademark Details

Filing Date

July 23, 2018

Registration Date

July 23, 2019

Published for Opposition

May 7, 2019

Cancellation Date

February 6, 2026

Goods & Services

SOFTWARE AND COMPUTER PROGRAMS FOR MEDICAL DIAGNOSIS; APPARATUS FOR PROCESSING MEDICAL DATA FOR DIAGNOSTIC PURPOSES; PROTECTION AND SECURITY EQUIPMENT FOR ESTABLISHING MEDICAL DIAGNOSTICS AND TESTS, NAMELY, GLOVES FOR LABORATORY PURPOSES, PROTECTIVE SUITS ESPECIALLY MADE FOR USE IN LABORATORIES, PROTECTIVE MASKS AND SPECTACLES

HUMAN AND VETERINARY MEDICINE, NAMELY, DIAGNOSTIC PREPARATIONS FOR DIAGNOSING AND PREDICTING BILHARZIA, CANCER, FIBROSIS, KELOID SCAR, CIRRHOSIS, DIABETES, CARDIAC DISEASE, FOR PREPARING SAMPLES, MODIFYING AND MANIPULATING CELLS AND FOR MARKING, SEPARATING, ISOLATING, REPRODUCING AND CLEANING BIOPOLYMERS, NUCLEIC ACIDS, PROTEINS, MACROMOLECULES AND BIOLOGICALLY ACTIVE SUBSTANCES; CHEMICAL, BIOCHEMICAL AND BIOTECHNOLOGICAL REAGENTS, SOLVENTS AND INDICATORS, ALL FOR MEDICAL PURPOSES, FOR PREPARING SAMPLES, MODIFYING AND MANIPULATING CELLS, AND FOR MARKING, SEPARATING, ISOLATING, REPRODUCING AND CLEANING BIOPOLYMERS, NUCLEIC ACIDS, PROTEINS, MACROMOLECULES AND BIOLOGICALLY ACTIVE SUBSTANCES FOR DIAGNOSTIC USE, ALL FOR USE IN TREATING, DIAGNOSING AND PREDICTING BILHARZIA, CANCER, FIBROSIS, KELOID SCAR, CIRRHOSIS, DIABETES, CARDIAC DISEASE; KITS COMPRISING PHARMACEUTICAL PREPARATIONS FOR HUMAN OR VETERINARY MEDICAL DIAGNOSTIC USE FOR PREPARING SAMPLES, MODIFYING AND MANIPULATING CELLS AND FOR MARKING, SEPARATING, ISOLATING, REPRODUCING AND CLEANING BIOPOLYMERS, NUCLEIC ACIDS, PROTEINS, MACROMOLECULES AND BIOLOGICALLY ACTIVE SUBSTANCES, ALL FOR USE IN TREATING, DIAGNOSING AND PREDICTING BILHARZIA, CANCER, FIBROSIS, KELOID SCAR, CIRRHOSIS, DIABETES, CARDIAC DISEASE; PREPARATIONS FOR DETECTING GENETIC PREDISPOSITIONS FOR MEDICAL USE

MEDICAL DIAGNOSIS SERVICES; MEDICAL TESTING FOR THE DIAGNOSIS AND TREATMENT OF PERSONS; GENETIC ANALYSIS FOR MEDICAL USE; MEDICAL SCREENING; MEDICAL ADVICE REGARDING MEDICAL MATTERS; PROVIDING ON-LINE INFORMATION RELATING TO MEDICAL DIAGNOSIS AND DETECTION OF DISEASES

DEVELOPMENT OF NEW TECHNOLOGY FOR OTHERS IN THE FIELD OF GENETICS AND BIOTECHNOLOGY; DEVELOPMENT OF TOOLS IN THE FORM OF SOFTWARE FOR REGULATING, MODIFYING AND CHARACTERIZING THE STATUS OF DISEASES; SCIENTIFIC RESEARCH AND DEVELOPMENT OF BIOTECHNOLOGICAL PROCESSES FOR REGULATING, MODIFYING AND CHARACTERIZING THE STATUS OF DISEASES; RESEARCH AND DEVELOPMENT FOR OTHERS IN THE FIELD OF BIOTECHNOLOGY; CUSTOM MANUFACTURE AND SYNTHESIS OF DNA, BIOLOGICAL ORGANISMS, CELLS, VIRUSES, PATHOGENS AND SPECIAL GENETICALLY MODIFIED CELLS ACCORDING TO SPECIFICATIONS PROVIDED BY OTHERS FOR THE PURPOSE OF SCIENTIFIC, MEDICAL AND/OR LABORATORY RESEARCH; RESEARCH AND DEVELOPMENT FOR OTHERS IN THE FIELD OF GENE THERAPY, NAMELY, DNA, BIOLOGICAL ORGANISMS, CELLS, VIRUSES, PATHOGENS AND SPECIAL GENETICALLY MODIFIED CELLS FOR SCIENTIFIC OR MEDICAL USE OR FOR RESEARCH; DEVELOPMENT AND DESIGN OF ALGORITHMS, DIAGNOSTIC APPARATUS, METHODS AND COMPUTER SOFTWARE IN THE MEDICAL FIELD; SCIENTIFIC RESEARCH IN THE FIELD OF GENETICS AND GENETIC ENGINEERING; MEDICAL RESEARCH; GENETIC RESEARCH; BIOLOGICAL RESEARCH SERVICES; CONDUCTING CLINICAL TRIALS FOR OTHERS; RESEARCH AND DEVELOPMENT OF MEDICAL TREATMENTS AND MEDICINES

Filing History

CANCELLED SECTION 71
Feb 6, 2026 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jul 23, 2024 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Jun 17, 2023 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Jul 17, 2021 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 6, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 18, 2019 FICS
FINAL DISPOSITION PROCESSED
Nov 18, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 23, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 23, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 7, 2019 NPUB
PUBLISHED FOR OPPOSITION
May 7, 2019 PUBO
NOTIFICATION PROCESSED BY IB
May 3, 2019 GPNX
CORRECTION SENT TO IB
Apr 30, 2019 CRSN
CORRECTION CREATED FOR IB
Apr 30, 2019 CRCR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 17, 2019 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 17, 2019 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 17, 2019 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 29, 2019 CNSA
REFUSAL PROCESSED BY IB
Mar 29, 2019 RFNT
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 27, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 27, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 19, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 18, 2019 GNRN
NON-FINAL ACTION E-MAILED
Jan 18, 2019 GNRT
NON-FINAL ACTION WRITTEN
Jan 18, 2019 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 19, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 19, 2018 CRFA
ASSIGNED TO LIE
Dec 19, 2018 ALIE
REFUSAL PROCESSED BY IB
Dec 15, 2018 RFNT
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 14, 2018 TROA
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 27, 2018 RFCS
REFUSAL PROCESSED BY MPU
Nov 27, 2018 RFRR
APPLICATION FILING RECEIPT MAILED
Nov 13, 2018 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 11, 2018 RFCR
NON-FINAL ACTION WRITTEN
Nov 10, 2018 CNRT
ASSIGNED TO EXAMINER
Nov 8, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 7, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 1, 2018 REPR